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T cell acute lymphoblastic leukemia (T-ALL) is 
a neoplastic disorder that occurs in 15% of 
pediatric and 25% of adult acute lymphoblastic 
leukemias. The TAL1/SCL gene (hereafter   
referred to as TAL1) is activated by chromo-
somal translocation, interstitial deletion, or un-
known mechanisms in >40% of human T-ALLs 
(Bash et al., 1995; Ferrando et al., 2002, 2004; 
Armstrong and Look, 2005). This activation re-
sults in the production of a normal TAL1 protein 
ectopically expressed from the double-negative 
stage onwards during T-lymphopoiesis, whereas 
during normal T cell differentiation, TAL1 ex-
pression is restricted to the DN1-DN2 subset of 
immature CD4/CD8 thymocytes (Herblot 
et al., 2000).
TAL1 encodes a class II basic helix-loop-
helix (HLH [bHLH]) transcription factor that 
can activate or repress genes by forming E-box 
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TAL1 (also known as SCL) is expressed in >40% of human T cell acute lymphoblastic 
leukemias (T-ALLs). TAL1 encodes a basic helix-loop-helix transcription factor that can 
interfere with the transcriptional activity of E2A and HEB during T cell leukemogenesis; 
however, the oncogenic pathways directly activated by TAL1 are not characterized. In this 
study, we show that, in human TAL1–expressing T-ALL cell lines, TAL1 directly activates 
NKX3.1, a tumor suppressor gene required for prostate stem cell maintenance. In human  
T-ALL cell lines, NKX3.1 gene activation is mediated by a TAL1–LMO–Ldb1 complex that is 
recruited by GATA-3 bound to an NKX3.1 gene promoter regulatory sequence. TAL1-
induced NKX3.1 activation is associated with suppression of HP1- (heterochromatin 
protein 1 ) binding and opening of chromatin on the NKX3.1 gene promoter. NKX3.1 is 
necessary for T-ALL proliferation, can partially restore proliferation in TAL1 knockdown 
cells, and directly regulates miR-17-92. In primary human TAL1–expressing leukemic cells, 
the NKX3.1 gene is expressed independently of the Notch pathway, and its inactivation 
impairs proliferation. Finally, TAL1 or NKX3.1 knockdown abrogates the ability of human  
T-ALL cells to efficiently induce leukemia development in mice. These results suggest that 
tumor suppressor or oncogenic activity of NKX3.1 depends on tissue expression.
© 2010 Kusy et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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1998). A thorough understanding of additional genes directly 
activated by TAL1 in T-ALL will provide greater insight into 
the mechanisms by which TAL1 induces or maintains a leu-
kemic phenotype.
To characterize genes directly or indirectly regulated by 
TAL1 in human T-ALL, we combined TAL1 knockdown 
by RNA interference and gene expression profiling in human 
T cell lines that express high or low levels of TAL1 protein. 
In addition to already known TAL1 target genes, we have 
identified the NKX3.1 gene as a potential TAL1 target gene 
in human T-ALL. NKX3.1 is a homeobox gene switched on 
during embryonic development of prostate tissue and then 
specifically expressed in the adult prostate epithelium (Shen 
and Abate-Shen, 2003). NKX3.1 is crucial for prostate stem 
cell maintenance (Wang et al., 2009), and its inactivation is 
one of the earliest events that occurs in prostate cancer initia-
tion, thus defining NKX3.1 as a major tumor suppressor gene 
of prostate cancer (He et al., 1997; Abdulkadir et al., 2002; 
Magee et al., 2003). We show that TAL1 directly activates the 
transcription of the human NKX3.1 gene by binding to reg-
ulatory sequences that are not conserved in the mouse Nkx3.1 
gene, suggesting differences between human TAL1-expressing 
T-ALL and mouse models of TAL1-mediated T-ALL. Finally, 
we document the role of NKX3.1 in human T-ALL both 
in vitro and in vivo.
RESULTS
TAL1 knockdown results in decreased proliferation  
of human T-ALL cell lines
We decreased TAL1 protein level using a lentiviral delivery 
of shTAL1 in four human T-ALL cell lines (Jurkat, HSB2, 
CEM, and RPMI) that express high (Jurkat and RPMI) or 
low (HSB2 and CEM) levels of TAL1 protein (Fig. 1 a and 
Fig. S1 a). Growth curves of the four T-ALL cell lines 
showed that TAL1 knockdown impaired proliferation of 
these cell lines, but only when the cells were grown in low 
(<2.5%) concentrations of FCS (Fig. 1 a, bottom; Fig. S1 b; 
and not depicted for RPMI and CEM). These effects were 
obtained with another shTAL1, indicating little or no off-
targets effects (unpublished data). To determine on which 
cellular functions TAL1 was acting, doubling time, apopto-
sis, and cell cycle of Jurkat and HSB2 cell lines expressing 
shCTL or shTAL1 were analyzed during the first 3 d of cul-
ture to avoid side effects caused by over-growth of leuke-
mic cells. TAL1 knockdown lengthened the doubling time 
of cells (Fig. 1 a, bottom) but affected neither apoptosis nor 
necrosis (not depicted). Cell cycle analyses showed fewer 
cells in G1 phase and more cells in G2/M phase (Jurkat) or 
S phase (HSB2; Fig. 1 b). BrdU pulse chase labeling of Jurkat 
cells showed that TAL1 knockdown induced a partial block-
age of the G2/M to G1 transition (Fig. 1 c, left), and diminished 
uptake of BrdU in HSB2 cells indicated a slow progression 
in S phase (Fig. 1 c, right). Thus, TAL1 knockdown re-
sulted in an impaired proliferation under low serum condi-
tions as the result of modifications of different phases of the 
cell cycle.
(CANNTG)–binding heterodimers with ubiquitous class I 
bHLH partners known as E-proteins, which include products 
of the E2A gene (E12 and E47), HEB, and E2-2 (Hsu et al., 
1991, 1994a; Voronova and Lee, 1994). In hematopoietic 
cells, TAL1 regulates the transcriptional activities of its target 
genes through binding to an E-box/GATA motif and nucle-
ation of a large complex that includes an E-protein, the LIM-
only protein LMO2, GATA-1/2, Ldb1, and other associated 
transcription factors (Wadman et al., 1997; Lécuyer et al., 
2002; Xu et al., 2003) or through its recruitment to regula-
tory sequences after interaction with GATA factors bound 
to DNA (Lahlil et al., 2004; Fujiwara et al., 2009; Yu et al., 
2009). Functionally, TAL1 is a master regulatory protein of 
primitive and definitive hematopoiesis and in the develop-
ment and maintenance of immature hematopoietic progen-
itors (Porcher et al., 1996; Robb et al., 1996; Brunet de la 
Grange et al., 2006; Souroullas et al., 2009; Lacombe et al., 
2010). These TAL1 functions suggest that this transcription 
factor might have an important role during initiation or main-
tenance of T cell leukemia, but the transcriptional pro-
grams directly regulated by TAL1 in human T-ALL are still 
being elucidated.
The prevailing model of TAL1-induced leukemogenesis 
describes TAL1 as a transcriptional repressor through its het-
erodimerization with E-proteins and blocking the E2A, 
HEB, and/or E2-2 transcriptional activities (Park and Sun, 
1998; O’Neil et al., 2004) and/or through a DNA binding–
independent sequestration mechanism similar to that pro-
posed for the Id family of HLH proteins (Benezra et al., 1990; 
Engel and Murre, 2001). This view is supported by the fact 
that  E2A/,  HEB/,  and  Id2–overexpressing  transgenic 
mice exhibit a defect in T cell differentiation, characterized 
by a block at the transition of CD4/CD8 double-negative to 
double-positive thymocytes and by the emergence of T-ALL 
in surviving E2A-deficient mice or Id-overexpressing mice 
(Bain et al., 1997; Yan et al., 1997; Morrow et al., 1999). At 
the molecular level, TAL1 might exert its inhibitory effects 
on E-protein target genes by interfering with E2A-mediated 
recruitment of chromatin-remodeling complexes that facili-
tate transcription activation (Bradney et al., 2003) and/or by 
recruitment of corepressors such as mSin3A and HDAC1 
(Huang and Brandt, 2000; O’Neil et al., 2004) or Brg1 and 
HDAC2 (Xu et al., 2006) on E2A, HEB, or E2-2 target genes.
In addition to the inhibition of class I bHLH functions, 
TAL1 might also exert its oncogenic effects through inap-
propriate gene activation. This possibility has been suggested 
by Ono et al. (1998), who have shown that TAL1 can induce 
the expression of the RALDH2 gene and is strengthened by the 
recent observation of a transcriptional regulatory network 
downstream of TAL1 in human T-ALL, showing that TAL1 
might act as a repressor or an activator of target genes   
(Palomero et al., 2006). Interestingly, rather than requiring 
an E-box motif, activation of the RALDH2 gene by TAL1 
occurred through its recruitment to a cryptic intronic pro-
moter by DNA-bound GATA-3, although the relevance of this 
target gene for leukemogenesis remains unknown (Ono et al., JEM VOL. 207, September 27, 2010 
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both cell lines was found (Fig. S2; deposited 
in  ArrayExpress  under  accession  no.   
E-MEXP-2197). Among these genes, we 
found already known TAL1 target genes 
such as RAG1, TM4SF2, or RALDH2 
(Ito et al., 2003; Ono et al., 1998; Soulier 
et al., 2005), thus validating the cell lines 
used to identify TAL1 target genes in 
human T-ALL.
Among potential TAL1 target genes, 
we focused our study on the NKX3.1 
gene as (a) this gene is not expressed in 
normal human thymocytes but is ectopi-
cally expressed in primary T-ALL samples 
expressing TAL1 (Soulier et al., 2005), 
(b) NKX2.5, another member of the NKX 
homeobox  protein  family,  is  activated   
by chromosomal translocations in a small 
number of primary human T-ALL and T cell lines (Nagel 
et al., 2003; Przybylski et al., 2006), and (c) NKX3.1 is in-
volved in the maintenance of prostate stem cells and is a 
tumor suppressor gene of prostate cancer (Magee et al., 2003; 
Wang et al., 2009). NKX3.1 protein level correlated with 
TAL1 protein level in the four T-ALL cell lines studied 
(Fig.  2  a),  and  NKX3.1  messenger  RNA  (mRNA)  and 
NKX3.1 protein levels were three- to fourfold decreased 
when TAL1 expression was decreased in Jurkat and HSB2 
cells using shTAL1 constructs (Fig. 2, b and c). These results 
indicated that NKX3.1 gene expression was dependent on 
Reduced TAL1 expression in Jurkat or HSB2 T cell lines  
is associated with up- or down-regulation of a common set 
of genes that includes the NKX3.1 gene
To identify TAL1 target genes involved in the proliferation 
of T-ALL cell lines, we performed gene expression profil-
ing of Jurkat and HSB2 cell lines expressing shTAL1 or 
shCTL. We isolated RNA from Jurkat and HSB2 cells after 
2 or 3 d of culture and used them to interrogate Affymetrix 
DNA microarrays representing 30,000 known human genes. 
Transcription profiles were compared, and a common set of 
genes for which expressions were dependent on TAL1 in 
Figure 1.  TAL1 regulates proliferation of 
Jurkat and HSB2 T-ALL cell lines. (a, top) TAL1 
protein in Jurkat and HSB2 cells that stably ex-
pressed shRNAs directed against human TAL1 
(shTAL1) or hepatitis B virus (shCTL) was mea-
sured by immunoblotting. Actin is shown as a 
loading control. The data shown correspond to a 
representative experiment out of two performed. 
(middle) Growth curves of Jurkat and HSB2 cells 
expressing shTAL1 or shCTL. Graphs show num-
ber of cells ± SEM (n = 4 experiments). (bottom) 
doubling times of Jurkat and HSB2 cells express-
ing shCTL or shTAL1 analyzed during the expo-
nential phase of the growth curves (***, P < 0.001). 
(b) Percentages of Jurkat (left) and HSB2 (right) 
cells expressing shCTL or shTAL1 in G1, S, and 
G2/M phases were determined at days 1, 2, and 3 
of culture. Graphs show percentages of cells ± 
SEM (n = 4 experiments; *, P < 0.05; **, P < 0.01). 
(c, left) Percentages of BrdU-negative Jurkat cells 
expressing shCTL or shTAL1 cycling from G2/M to 
G1 were determined at days 1, 2, and 3 of cul-
ture. (right) BrdU mean fluorescence of HSB2 
cells expressing shCTL or shTAL1 labeled with 
BrdU at days 1, 2, and 3 of culture. Graphs show 
percentages of cells ± SEM (n = 4 experiments; 
**, P < 0.01). MFI, mean fluorescence intensity.2144 NKX3.1 drives human T-ALL | Kusy et al.
This region contains multiple E-boxes and GATA binding 
sites (Fig. S3 a), and using oligonucleotides that cover all 
E-boxes and GATA binding sites present in the 875/570 
human NKX3.1 promoter region, we found that TAL1 and 
GATA-3 can bind an E-box located at 738 and/or two 
GATA binding sites at 748 and 697 (Fig. 3 c). To iden-
tify the relative contributions of these three regulatory motifs to 
the transcriptional activity of the NKX3.1 gene promoter, the 
977/482  sequence  and  associated  mutants  at  positions 
748/738 and/or 697 were cloned upstream of a minimal 
promoter that drives luciferase expression and used in tran-
sient transfection assays. This promoter region could activate 
transcription in Jurkat cells (Fig. 3 d) but not in NIH3T3 cells 
(not depicted), and this activation was dependent on TAL1 
expression (Fig. 3 d). Transcriptional activities of the different 
mutants of the 977/482 promoter region pinpointed the 
GATA-3–TAL1 binding site at 697 as a major regulatory 
site that mediated the transcriptional activity of this NKX3.1 
promoter region in Jurkat cells (Fig. 3 d). Interestingly, the 
two regulatory sequences that can bind TAL1 in the human 
NKX3.1 gene are not conserved in the mouse gene (Fig. S3 a), 
and as a consequence, no transcriptional activity of the corre-
sponding mouse Nkx3.1 promoter region could be detected 
in Jurkat cells (Fig. 3 d). These results suggest why increased 
Nkx3.1 mRNA levels are not found in gene expression pro-
filing of mouse TAL1–LMO1 leukemic cells (Fig. S3 b).
At the chromatin level, GATA-3 was bound to the 
NKX3.1 promoter in T cell lines expressing or not NKX3.1 
(Fig. 4 a, top left). Expression of TAL1 led to its recruitment 
by GATA-3 (Fig. 4 a, top right) and to the formation of a 
transcriptional complex containing LMO1/2 and Ldb1 pro-
teins on the NKX3.1 promoter (Fig. 4 a, bottom). Recruit-
ment (respectively suppression) of this complex on the NKX3.1 
promoter was associated with suppression (respectively recruit-
ment) of HP1- (heterochromatin protein 1 ) binding and 
histone H3 trimethylation on lysine 9, which are hallmarks of 
gene repression (Fig. 4 b, left). The effects of TAL1 knock-
down on activating (H3K14ac or H3K4me3) or repressive 
(H3K27me3) histone marks further strengthened a TAL1-
dependent chromatin structure of the NKX3.1 gene promoter 
in the Jurkat cell line (Fig. 4 b, right). The NKX3.1 gene acti-
vation is similar to the TAL1-mediated RALDH2 gene 
activation in human T-ALL (Ono et al., 1998). We found 
TAL1-dependent chromatin modifications of the RALDH2 
gene similar to the ones found on the NKX3.1 promoter 
(Fig. S4), indicating that TAL1 might regulate the chromatin 
structure of a subset of genes already marked by GATA-3. As 
the GATA-3–TAL1 interaction nucleates a transcriptional 
complex containing Ldb1 and LMO1 in Jurkat cells, the ex-
pression of GATA-3, Ldb1, and LMO1 was knocked down 
after transduction of Jurkat cells by lentiviruses that could 
express short hairpin RNAs (shRNAs) targeting the cor-
responding mRNAs (Fig. 5 a), and the NKX3.1 mRNA level 
was quantified in the transduced cell line. NKX3.1 mRNA 
level was not affected by overexpression of E12, indicating that 
NKX3.1 gene expression was not dependent on E2A protein 
the presence of TAL1 in T cell lines and suggested a possible 
function of the NKX3.1 protein in TAL1-mediated prolifer-
ation of human T-ALL.
The human NKX3.1 gene is directly activated by TAL1  
in T-ALL cell lines through regulatory sequences  
that are not conserved in the mouse Nkx3.1 gene
To determine whether TAL1 could directly activate transcrip-
tion of the NKX3.1 gene, we first expressed TAL1 in a human 
T cell line, Peer, which expresses neither TAL1 nor NKX3.1. 
Ectopic expression of TAL1 in Peer cells resulted in the tran-
scriptional activation of the endogenous NKX3.1 gene and 
expression of the NKX3.1 protein (Fig. 3 a), indicating that 
the NKX3.1 gene is a potential direct target of TAL1. Chro-
matin immunoprecipitation (ChIP) showed that TAL1 and 
GATA-3, the only member of the GATA family expressed in 
T cells, were specifically bound in vivo to the 875/570 
region of the human NKX3.1 gene promoter (Fig. 3 b). 
Figure 2.  NKX3.1 mRNA and protein levels are dependent on TAL1 
expression. (a) TAL1 and NKX3.1 protein in high (Jurkat and RPMI) and 
low (CEM and HSB2) TAL1-expressing T cell lines was measured by immuno-
blotting. Actin is shown as a loading control. The data shown correspond 
to one representative experiment out of two performed. Vertical black 
lines indicate that intervening lanes have been spliced out. (b) NKX3.1 
mRNA was determined by quantitative RT-PCR normalized to GAPDH 
mRNA in shCTL- or shTAL1-expressing T cell lines. Error bars indicate SEM 
(n = 4 experiments). (c) NKX3.1 protein was measured by Western blotting 
using nuclear extracts from the indicated T cell lines. Actin is shown as a 
loading control. The data shown correspond to one representative experi-
ment out of three performed.JEM VOL. 207, September 27, 2010 
Article
2145
increased doubling time, and did not affect apoptosis/necro-
sis of the cells (Fig. 6 a, bottom; and not depicted). NKX3.1 
protein level was more reduced with shNKX3.1 than with 
shTAL1 (Fig. S5 b), indicating why the effects on cell growth 
of NKX3.1 knockdown could be more dramatic than TAL1 
knockdown. In Jurkat and HSB2 cells, NKX3.1 knockdown 
also had effects on the cell cycle similar to those of TAL1; 
i.e., it diminished the percentage of cells in G1 phase and in-
creased the percentage of cells in G2/M phase (Jurkat) or 
in S phase (HSB2; Fig. 6 b). Finally, constitutive expression 
of NKX3.1 in shTAL1-expressing Jurkat and HSB2 cells 
(Fig. 6 c, top) rescued the proliferative deficiency associated 
with low TAL1 expression but did not prevent cell death 
(Fig. 6 c, bottom).
To identify common target genes regulated by TAL1 and 
NKX3.1 knockdown, we performed gene expression profil-
ing of Jurkat and HSB2 T cell lines expressing shNKX3.1, 
shTAL1, or shCTL. We isolated RNAs from cells after 2 d 
of culture and used them to interrogate Affymetrix DNA 
microarrays. Transcription profiles were compared, and we 
characterized a common set of genes possibly involved in 
leukemic cell proliferation and for which expressions were 
level but decreased when the protein level of any member of 
the TAL1-containing complex decreased (Fig. 5 b). Alto-
gether, these results indicated that ectopic expression of TAL1 
in human T-lymphoid cells could activate the transcription of 
the human gene NKX3.1 at its chromosomal locus via TAL1 
recruitment by GATA-3 already bound to the NKX3.1 pro-
moter and formation of a nuclear complex that can eliminate 
repression of the NKX3.1 gene.
NKX3.1 is required for the proliferation  
of TAL1-expressing T cell lines
NKX3.1-deficient mice develop prostatic hyperplasia, and 
NKX3.1 has been shown to regulate cell cycle exit during 
luminal cell regeneration, indicating that NKX3.1 has an 
antiproliferative effect in the prostate (Lei et al., 2006). As the 
NKX3.1 gene is activated by TAL1 in human T cell lines, we 
studied the role of NKX3.1 in the cellular proliferation of 
Jurkat and HSB2 cell lines expressing shNKX3.1. NKX3.1 pro-
tein level was decreased using two different shNKX3.1 lenti-
viral constructs (Fig. 6 a, top; and not depicted). NKX3.1 
knockdown impaired proliferation of Jurkat and HSB2 cells 
cultured in low (<2.5%) FCS concentrations (Fig. S5 a), 
Figure 3.  TAL1 directly activates NKX3.1 gene expression in human T cell lines. (a) Peer, a T-ALL cell line which expresses neither TAL1 nor 
NKX3.1, was transduced with lentiviral particles containing TAL1 cDNA. Expression of TAL1 (left) and NKX3.1 (right) mRNA was studied in Peer cells (Peer NT) 
or in Peer cells expressing TAL1 (Peer TAL1) by quantitative PCR normalized to GAPDH mRNA. Error bars indicate SEM (n = 4 experiments). (b) The  
human 875/570 NKX3.1 promoter region (+1 is the ATG start codon) contains E-boxes (open boxes) and GATA binding sites (gray boxes). Arrows indi-
cate positions of oligonucleotides used for PCR amplification. Jurkat cell chromatin extract was immunoprecipitated with GATA-3, TAL1 antibodies, or 
control-matched Ig (m., mouse; r., rabbit). Immunoprecipitated DNA was amplified to detect the 790/570 NKX3.1 promoter or exon 2 sequences. Input 
is amplification of Jurkat cell DNA. The results shown are representative of four independent experiments. (c) Jurkat cell nuclear extract was incubated 
with biotin-labeled oligonucleotides that covered E-boxes and/or GATA binding sites present in the 875/570 NKX3.1 promoter region. Proteins bound 
to the different oligonucleotides were analyzed by Western blot using GATA-3 or TAL1 antibodies. The data shown correspond to one representative 
experiment out of three performed. (d) Jurkat cells expressing shCTL or shTAL1 were transfected with plasmids containing wild-type or mutated 
977/482 sequence of the NKX3.1 gene promoter cloned upstream of a minimal promoter that drives the firefly luciferase (LUC) gene. The mutated 
sequences, indicated by crosses, abolished GATA-3 and/or TAL1 binding sites. The corresponding mouse Nkx3.1 gene promoter region was cloned up-
stream of the same reporter gene and assayed in Jurkat cells. Transfections were normalized using the dual-luciferase reporter assay system, and expres-
sion of Renilla luciferase provides an internal control. Data are the means ± SEM (n = 4 experiments).2146 NKX3.1 drives human T-ALL | Kusy et al.
decreased E2F1 protein level without any significant de-
crease of E2F1 mRNA level (Fig. 7 a). NKX3.1 could bind 
a miR-17-92 gene region located 4 kb 5 from the transcription 
start site (Fig. 7 b). This binding is associated with increased 
(vs. decreased) binding of histone H3 marked with repressive 
label (vs. activating label; H3K27me3 vs. H3K14ac) on this 
regulatory sequence (Fig. 7 c), and NKX3.1 could repress tran-
scriptional activity of the 4-kb regulatory sequence of 
the miR-17-92 gene (Fig. 7 d). Finally, quantitative PCR 
analysis of pri-miR-17-92 showed that its expression level 
inversely correlated with TAL1 and NKX3.1 expressions 
(Fig. 7 e). These results identified miR-17-92 as a direct tar-
get of NKX3.1 in the Jurkat cell line. Altogether, these results 
showed that NKX3.1 could mediate the proliferative effects 
of TAL1 in T cell lines through a direct regulation of a spe-
cific set of genes.
dependent on TAL1 and NKX3.1 expressions (Fig. S6 a; de-
posited in ArrayExpress under accession no. E-MEXP-2197). 
Most genes have an expression dependent on TAL1 and/or 
NKX3.1, whereas few genes have an expression dependent 
only on NKX3.1, indicating NKX3.1 as a mediator of TAL1-
regulated pathways (Fig. S6 b).
MicroRNAs (miRNAs) are expressed in human T-ALL 
(Chen et al., 2010), and the oncogenic 17-92 cluster of miRNAs 
is  of  high  importance  in  human  hematopoietic  cancers 
(Mavrakis et al., 2010). Furthermore, miR-17-92 regulates 
expression of E2F1 and thus of the cell cycle (Nagel et al., 
2009), and miR-19, a member of the miR-17-92 cluster, is 
sufficient to promote leukemogenesis in Notch1-induced T-ALL 
(Mavrakis et al., 2010). As NKX3.1 knockdown results in 
growth inhibition, we studied E2F1 expression in Jurkat cells 
expressing shCTL, shTAL1, or shNKX3.1 and showed a 
Figure 4.  TAL1 expression modifies the chromatin structure of the NKX3.1 gene promoter. (a) Jurkat shCTL, Jurkat shTAL1, Peer NT, and Peer 
TAL1 cell chromatin extracts were immunoprecipitated with GATA-3 (top left), TAL1 (top right), LMO1/2 (bottom left), and Ldb1 (bottom right) antibodies, 
control-matched Ig, or no antibody (no Ab). Immunoprecipitated DNA was amplified to detect the 790/570 NKX3.1 promoter region as in Fig. 3 b. The 
data shown correspond to one representative experiment out of two performed. (b, left) HP1-, me3H3K9 antibodies, or control Ig was used to immuno-
precipitate the same chromatin extracts as in panel a. NKX3.1, Pax6 (repressed gene), and Bmi (activated gene) promoter sequences were detected by 
quantitative PCR on the immunoprecipitated DNA. (right) H3K14ac, H3K4me3, and H3K27me3 antibodies or control Ig was used to immunoprecipitate 
chromatin extracts from Jurkat shCTL and Jurkat shTAL1. NKX3.1 promoter sequence was detected by quantitative PCR on the immunoprecipitated DNA. 
Data are the means ± SEM (n = 3 experiments; **, P < 0.01).JEM VOL. 207, September 27, 2010 
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DISCUSSION
The class II bHLH factor TAL1 is aberrantly expressed in 
60% of children and in 45% of adults with T-ALL, but the 
mechanisms that mediate its oncogenic potential remain un-
clear (O’Neil and Look, 2007). Using RNA interference to 
knock down TAL1 expression in human T-ALL cell lines 
that express low or high levels of TAL1 protein, we showed 
that TAL1 regulates proliferation in these cell lines. These 
results are in accordance with a previously described role for 
TAL1 in promoting the aberrant growth of Jurkat cells with-
out any effect on apoptosis (Palomero et al., 2006). The ef-
fects observed on Jurkat and HSB2 cell proliferation shown 
in this article are particularly drastic as we used lentiviruses 
that transduce 100% of cells and consequently eliminate any 
potential side effects, such as affecting clonal selection. More-
over, the cell culture conditions used (i.e., 1% FCS) allowed 
us to detect this drastic effect of TAL1 knockdown on prolif-
eration, indicating that growth factors present in the serum 
can complement some of the oncogenic effects of TAL1.
To study the TAL1 network that regulates the prolifera-
tion of T-ALL cell lines, we performed gene expression pro-
filing using oligonucleotide microarrays after 2 or 3 d of 
culture of Jurkat or HSB2 cell lines expressing or not TAL1. 
We focused our study on a set of genes whose transcriptional 
activity was dependent on TAL1 expression in both cell 
lines. Some of these genes, like Six6, RAG2, or RALDH2, 
have been shown to be specifically expressed in TAL1- 
expressing primary T-ALL blasts (Soulier et al., 2005), indi-
cating that our screening might be more relevant to human 
T-ALL biology than to cell line–associated secondary events. 
No obvious metabolic pathway regulated by TAL1 expres-
sion could be deduced from the analysis of the set of genes 
characterized in the two cell lines, and our results indicated 
that TAL1 might act as an activator or a repressor in human 
T-ALL, a feature previously suggested (Hsu et al., 1994b; 
Palomero et al., 2006).
Among the genes whose expression depends on TAL1, we 
focused our study on NKX3.1, a member of the NKX family of 
homeobox genes that is specifically expressed in the prostate 
NKX3.1 expression, regulation, and function in primary 
human T-ALL
As cell lines may not reliably reflect patient samples, TAL1 and 
NKX3.1 mRNA levels were quantified in human primary cir-
culating T-ALL blasts, and these quantifications showed a 
correlation between TAL1 and NKX3.1 expressions (Fig. 8 a). 
T-ALLs proliferate in bone marrow and other organs, but 90% 
of the circulating blasts are in the G0 phase and do not proliferate 
(Fig. S7 a, left). Therefore, to study any role of TAL1 and 
NKX3.1 in proliferation of leukemic cells, we used the previ-
ously described MS5-DL1 mouse stromal cell line, which allows 
activation, maintenance, and proliferation of primary T-ALL 
leukemic cells in vitro (Fig. S7 a [right panel] and b; Armstrong 
et al., 2009). Four human T-ALL primary samples that express 
(M18, M61, and M69) or do not express (M30) TAL1 were 
grown on MS5-DL1. TAL1 and NKX3.1 mRNA levels were 
10 times higher in M18 and M61 leukemic proliferating cells 
than in M18 or M61 circulating blasts, and these mRNAs were 
not detected in M30 proliferating cells (Fig. 8 b, top). These in-
creased mRNA levels were mostly related to proliferation and 
not to activation of the Notch signaling pathway, as shown by 
the effect of DAPT, an inhibitor of this pathway, on TAL1 and 
NKX3.1 mRNA levels (Fig. S7 c) and on Ki67-positive leuke-
mic cells (Fig. S7 d). Decreased TAL1 or NKX3.1 expression 
abrogated proliferation of M18, M61, and M69 but not of M30 
leukemic cells, indicating that these two proteins were necessary 
for proliferation of primary TAL1-expressing T-ALL leukemic 
cells (Fig. 8 b, bottom). Decreased TAL1 or NKX3.1 expression 
also impaired leukemia development in vivo as leukemia devel-
opment from shTAL1- or shNKX3.1-expressing M18 leukemic 
cells was limited compared with control cells after transplanta-
tion into immunodeficient mice (Fig. 8 c, top). Furthermore, 
NKX3.1 or TAL1 expression was detected in the leukemias that 
developed in mice, indicating that only blasts with little inhibi-
tion of TAL1 or NKX3.1 could escape from the proliferation 
defect and were selected and responsible for T-ALL leukemia 
development (Fig. 8 c, bottom). These results show that TAL1 
and NKX3.1 are involved in efficient development of human 
T-ALL in recipient immunodeficient mice.
Figure 5.  LMO1, Ldb1, and GATA-3 pro-
teins are necessary for NKX3.1 expression 
in Jurkat cells. (a) shRNAs directed against 
LMO1, Ldb1, and GATA-3 decreased the cor-
responding protein level compared with cells 
expressing an shCTL. Jurkat cells were also 
transduced with a lentivirus that allowed 
overexpression of the E12 or GFP protein. 
Nuclear extracts from transduced Jurkat cells 
were analyzed by Western blotting using the 
indicated antibodies. Actin is shown as a load-
ing control. The data shown correspond to 
one representative experiment out of two 
performed. Vertical black lines indicate that 
intervening lanes have been spliced out. (b) NKX3.1 mRNA was monitored by quantitative RT-PCR normalized to GAPDH mRNA in Jurkat cells transduced 
with lentiviral vectors that expressed GFP, E12 cDNA, or control shRNA or shRNA directed against LMO1, Ldb1, or GATA-3. Data are the means ± SEM  
(n = 4 experiments).2148 NKX3.1 drives human T-ALL | Kusy et al.
Figure 6.  NKX3.1 mediates proliferating effects 
of TAL1 in human T cell lines. (a, top) NKX3.1 pro-
tein in Jurkat and HSB2 cells that stably expressed 
shRNAs directed against human NKX3.1 (shNKX3.1) or 
human hepatitis B virus (shCTL) was measured by 
immunoblotting. Actin is shown as a loading control. 
The data shown correspond to one representative 
experiment out of two performed. (middle) Growth 
curves of Jurkat and HSB2 cells expressing shNKX3.1 
or shCTL. Graphs show number of cells ± SEM (n = 4 
experiments). (bottom) Doubling times of Jurkat and 
HSB2 cells expressing shCTL or shNKX3.1 analyzed 
during the exponential phase of the growth curves. 
(b) Percentages of Jurkat (left) and HSB2 (right) cells 
expressing shCTL or shNKX3.1 in G1, S, and G2/M 
phases were determined at days 1, 2, and 3 of culture. 
Graphs show percentages of cells ± SEM (n = 3 ex-
periments; *, P < 0.05; **, P < 0.01). (c, top left) Jurkat 
and HSB2 cells were transduced with viral particles 
containing human NKX3.1 cDNA followed by an IRES/
EGFP under the control of the MND promoter. These 
cells were then transduced with viral particles con-
taining the EF1-–EGFP construct and shTAL1 under 
the control of the H1 promoter. Each transduction 
was 100% efficient as shown by FACS analysis of 
EGFP expression. Dashed lines and arrows determine 
the fluorescent population studied. (top right) Western   
blot analysis of TAL1 and NKX3.1 expression in shCTL- 
and shTAL1-expressing Jurkat cells. “NKX3.1 + shTAL1” 
defined the NKX3.1-expressing Jurkat cells transduced 
with the shTAL1 lentivirus. Actin is shown as a loading 
control. The data shown correspond to one represen-
tative experiment out of two performed. (bottom) 
Growth curves of Jurkat and HSB2 cells expressing 
shCTL, shTAL1, or shTAL1 and NKX3.1. Graphs show 
number of cells ± SEM (n = 4 experiments).
epithelium during prostate development and 
in adulthood. Only one member of the NKX 
family, NKX2.5, has already been charac-
terized as a master oncogene in human T-ALL. 
NKX2.5 is activated only by T-ALL–specific 
rearrangements (Przybylski et al., 2006) and is 
expressed in two T cell lines, Peer and CCFR-
CEM (Nagel et al., 2003). In accordance with 
previous studies, we did not find any expres-
sion of NKX2-5 in Jurkat, HSB2, or RPMI 
T cell lines but found NKX2.5 expression 
in  CCFR-CEM  cells  (Nagel et al., 2003; 
Przybylski et al., 2006). As TAL1 knock-
down (respectively expression) did not affect 
NKX2.5 expression in CCFR-CEM cells (re-
spectively Peer; unpublished data), we did not 
study any further NKX2.5 roles in T cell lines 
and focused our research on NKX3.1. We 
showed that the NKX3.1 gene is directly 
activated  by  TAL1  in  T-ALL  through  a 
GATA-3–mediated recruitment of a TAL1–
LMO–Ldb1 complex on regulatory sequences JEM VOL. 207, September 27, 2010 
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TAL1  functions  in 
erythropoiesis  and 
T cell leukemogen-
esis with a repres-
sive  or  activating 
function of TAL1 
depending on its recruitment to DNA. Finally, as for the 
RALDH2 gene, the regulatory sequences that mediated TAL1 
recruitment on the NKX3.1 gene promoter are not conserved 
between human and mouse, which suggests why the Nkx3.1 
gene is not activated in mouse models of TAL1-mediated 
T-ALL. Tissue-specific transcriptional regulation is markedly 
different between human and mouse. A recent study has shown 
that >50% of four tissue-specific transcription factor binding 
sites are species specific, and it is thus not surprising to find spe-
cific gene activations in human T-ALL that cannot be mimicked 
by mouse models (Odom et al., 2007). Together with works on 
of the NKX3.1 gene. This recruitment is associated with sup-
pression of the NKX3.1 gene repression at the chromatin level. 
This peculiar gene activation in human T-ALL is similar to the 
TAL1-mediated RALDH2 gene activation in T-ALL (Ono 
et al., 1998) and pinpoints GATA-3 as an important compo-
nent of TAL1 function in human T cell leukemogenesis. Dur-
ing erythropoiesis, a TAL1–LMO2–Ldb1–E2A complex can 
distinguish active from repressive GATA-1 binding sites as this 
complex is only present at activating elements and is not as-
sociated with repressive GATA-1 binding sites. In human 
T-ALL, TAL1–E2A direct binding to DNA is often associated 
with repression of target genes after recruitment of corepres-
sors such as LSD1 or HP1- (Wen et al., 2005; Hu et al., 2009), 
but we now showed that the recruitment of the TAL1–LMO–
Ldb1 complex by GATA-3 could relieve the repression of 
NKX3.1 and RALDH2 genes by antagonizing HP1- func-
tion. Altogether, these results indicated a similarity between 
Figure 7.  NKX3.1 directly regulates miR-
17-92 promoter activity. (a, left) E2F1 protein 
in shCTL-, shTAL1-, and shNKX3.1-expressing 
Jurkat cells at days 3 and 4 of culture was 
measured by immunoblotting. ERK1/2 is 
shown as a loading control. The data shown 
correspond to one representative experiment 
out of three performed. (right) E2F1 mRNA 
was determined by quantitative RT-PCR nor-
malized to GAPDH mRNA in the same T cell 
lines at days 3 and 4 of culture. Error bars 
indicate SEM (n = 4 experiments). (b, top) 
Schematic organization of the miR-17-92 
promoter region. The transcriptional start site 
(+1), TATA box (32), and exon 1 and E2F 
binding sites (+50 and +60) are indicated. The 
cluster of NKX3.1 consensus binding sites lo-
cated 4 kb upstream of the transcription start 
site is shown by blue boxes. Location of the 
primer set used in the ChIP analysis is shown 
by arrows. (bottom) Jurkat cell chromatin ex-
tract was immunoprecipitated with NKX3.1 
antibody or control Ig. Immunoprecipitated 
DNA was amplified to detect a 300-bp region 
located at 4 kb in the miR-17-92 promoter 
region. Input is amplification of Jurkat cell 
DNA. The data shown correspond to one repre-
sentative experiment out of two performed.  
(c) H3K27me3 and H3K14ac antibodies or 
control Ig was used to immunoprecipitate 
chromatin extracts from Jurkat shCTL or Jurkat 
shNKX3.1. The 4-kb miR-17-92 regulatory 
sequence was detected by quantitative PCR on 
the immunoprecipitated DNA. Data are the 
means ± SEM (n = 3 experiments; **, P < 0.01). 
(d) Jurkat cells were transfected with a plasmid 
containing the 4-kb miR-17-92 regulatory 
sequence that binds NKX3.1 cloned upstream 
of a promoter that drives the firefly luciferase 
gene with or without an NKX3.1 cDNA se-
quence. Transfections were normalized using 
the dual-luciferase reporter assay system. Data 
are the means ± SEM (n = 4 experiments).  
(e) miR-17-92 RNA was determined by quanti-
tative RT-PCR normalized to 36B4 RNA in  
shCTL, shTAL1, or shNKX3.1 Jurkat cells at  
days 3 and 4 of culture. Error bars indicate  
the SEM (n = 4 experiments).2150 NKX3.1 drives human T-ALL | Kusy et al.
rodent  cells  compared  with  human  cells  (Rangarajan  et  al., 
2004). Rodent cells seemed to need fewer events to be trans-
formed as two signaling pathways are required for tumorigenic 
conversion of normal mouse fibroblasts, whereas perturba-
tion of six pathways is required for the transformation of 
the transcriptional networks downstream of TAL1 in human 
T-ALL (Rangarajan et al., 2004; Soulier et al., 2005), our study 
indicates that mouse models of human T-ALL might recapitu-
late only part of human T cell leukemogenesis. Species-specific 
differences have already been described for transformation of 
Figure 8.  NKX3.1 is expressed in human TAL1-expressing T-ALL cells and is necessary for in vitro proliferation and in vivo development of 
human T-ALL. (a) TAL1 and NKX3.1 mRNA levels in human T-ALL blasts at diagnosis. Quantitative RT-PCR analysis of TAL1 and NKX3.1 mRNA was per-
formed using RNA prepared from blasts obtained from 15 human T-ALL. Relative expressions were normalized to 2m mRNA. Error bars represent means ± 
SEM (n = 4 experiments). (b, top) TAL1 and NKX3.1 mRNA levels were analyzed by quantitative RT-PCR using RNA extracted from TAL1-expressing (M18 
and M61) or non-TAL1–expressing (M30) T-ALL leukemic cells at diagnosis (black bars) or after 3 d of culture on the MS-5 cell line expressing the DL1 
Notch ligand (MS5-DL1; hatched bars). Relative expressions were normalized to 2m mRNA level. Error bars indicate SEM (n = 4 experiments).  
(bottom) Growth curves of M18, M61, M69, and M30 primary T-ALL expressing shCTL, shTAL1, or shNKX3.1 co-cultured with MS5-DL1 for 21 d (M69) or 1 mo.   
(c) M18 leukemic cells expressing shCTL, shTAL1, or shNKX3.1 were injected into NS and NSG mice. (top) percentages of human leukemic transduced 
(CD45+CD7+EGFP+) cells detected in bone marrow and spleen of mice at 6 (NSG) and 12 (NS) wk after transplantation. Median engraftment levels (hori-
zontal bars) are indicated under the diagram. (bottom) Quantitative RT-PCR analyses of TAL1 and NKX3.1 mRNA were performed using RNA from 
CD45+CD7+EGFP+ cells isolated from mice that developed leukemia (m1–m7). Relative expression levels were normalized to 2m mRNA level and repre-
sented by a color scale (n = 3 experiments).JEM VOL. 207, September 27, 2010 
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TAL1 and NKX3.1 in leukemia development, we used pa-
tient samples. We first studied TAL1 and NKX3.1 expression 
levels in primary samples from T-ALL patients and showed a 
correlation between NKX3.1 and TAL1 gene expressions, a 
result which is in accordance with previous data (Soulier et al., 
2005). However, as we observed that blood-derived T-ALL 
blasts are mostly quiescent cells, we switched to a cell culture 
system we recently showed to allow activation and/or prolif-
eration of T-ALL leukemic cells as well as preservation of 
T-ALL leukemia–initiating cell activity (Armstrong et al., 
2009). In this context, we found that TAL1 and NKX3.1 
gene expressions were increased >10 times in leukemic cells 
recovered after culture in comparison with uncultivated T-ALL 
blasts. These results suggested that caution should be exercised 
when using gene expression profiling of blood-derived T-ALL 
blasts, especially when studying genes involved in the ac-
tivation or proliferation of T-ALL cells. In the context of 
culture-activated leukemic cells, we found that the Notch 
pathway did not significantly regulate TAL1 and NKX3.1 
gene  expression,  indicating  that  the  TAL1–NKX3.1  and 
Notch pathways might cooperate in the development of 
human T-ALL. We finally showed that NKX3.1 expression 
is an important component of the development of human 
T-ALL in vivo as NKX3.1 knockdown in human T-ALL 
samples limited leukemia burden in immunodeficient mice. 
These results strengthen the importance of NKX3.1 gene ac-
tivation by TAL1 during human T cell leukemogenesis. Fur-
ther experiments are needed to establish whether NKX3.1 
and TAL1 participate in the maintenance and/or prolifera-
tion of T-ALL leukemia–initiating cell, as we have recently 
demonstrated for Notch (Armstrong et al., 2009).
In conclusion, the results described in this study charac-
terize NKX3.1 as the first gene directly activated by TAL1 in 
human T-ALL and involved in the proliferation of human 
T-ALL in vitro and in vivo. These findings extend the current 
view of TAL1-mediated T leukemogenesis, e.g., interference 
with the transcriptional regulation elicited by the tumor sup-
pressor gene E2A, and may define new pathways that could 
be used for the treatment of T-ALL.
MATERIALS AND METHODS
Cell lines, T-ALL samples, and culture conditions. Jurkat, HSB2, and 
Peer cells were maintained in RPMI 1640 containing 10% FCS (Invitrogen). 
Cells were grown in 10, 5, 2.5, and 1% FCS for the growth curve analysis, 
and viable cells were counted every day by trypan blue exclusion. Primary 
T-ALL samples were obtained and characterized (Armstrong et al., 2009) at 
diagnosis after informed consent of all patients’ parents, in accordance with 
national ethics rules, and cultured with mouse stromal MS5 cells as described 
previously (Armstrong et al., 2009).
Lentiviral vectors and cell transduction of cell lines and T-ALL pri-
mary samples. Oligonucleotides 5-GTTCAGCCATCAGAAGTAC-3 
(respectively 5-TGTGTCACTGAATATCAAC-3) were designed in the 
coding region of the human NKX3.1 gene and used for PCR amplification. 
The 230-bp DNA fragment obtained was purified and cloned in the pSuper 
plasmid 3 of the polIII H1 promoter. H1-shRNANKX3.1 DNA fragment 
was then subcloned in pTRIP/U3–EF1-–EGFP, where the GFP coding 
sequence is under the control of the EF1- promoter (TRIP/U3–EF1-–
EGFP; Sirven et al., 2001). The lentiviral vectors pTRIP/U3–EF1-–EGFP 
human fibroblasts (Rangarajan et al., 2004). Our results indi-
cated that TAL1-mediated leukemogenesis might also require 
less signaling pathways in mouse than in human and shows 
the importance of paralleled experiments in mouse and 
human leukemia and of mouse models of human leukemia.
What could be the role of NKX3.1, a tumor suppressor 
gene in human prostate cancer, in human T-ALL? To address 
this question, we first inhibited NKX3.1 gene expression in 
the different TAL1+/T-ALL cell lines studied and found a 
near failure of proliferation when the NKX3.1 protein was 
down-regulated. These results indicated that NKX3.1 could 
mediate some of the proliferative effects of TAL1 in T-ALL 
and complementation experiments of TAL1 knockdown by 
overexpression of NKX3.1 confirmed this hypothesis. Dur-
ing the prostate cancer initiation, NKX3.1 blocks some of 
the effects of PTEN loss and inhibits AKT phosphorylation 
(Lei et al., 2006). In human T-ALL, PTEN is frequently de-
leted (Maser et al., 2007), and thus the TAL1-mediated acti-
vation of NKX3.1 might block some of the effects of PTEN 
loss during TAL1-mediated T cell leukemogenesis. How-
ever, in Jurkat cells, which harbor a mutated PTEN protein, 
NKX3.1 knockdown did not result in a diminished AKT 
phosphorylation (unpublished data), indicating that NKX3.1 
regulated the proliferation of these cells using other path-
ways. The oncogenic function of NKX3.1 in human T-ALL 
might also be related to the role of NKX3.1 in cellular prolif-
eration of LNCaP, a hormone-sensitive model of prostate 
cancer (Possner et al., 2008). As NKX3.1 might have differ-
ent roles during prostate cancer progression, including a role 
in proliferation at the early steps of prostate carcinogenesis, 
our results indicated that NKX3.1 might only have prolifera-
tive functions in human T-ALL. To determine the metabolic 
pathways regulated by NKX3.1 and TAL1 in human T-ALL, 
we  performed  and  analyzed  gene  expression  profiling  and 
found a common set of genes for which transcription was de-
pendent  on  TAL1  and  NKX3.1  expression  in  Jurkat  and 
HSB2. Among these genes, two subsets could be related to 
the growth curves previously obtained. The first one contains 
genes known to be involved in the T cell signaling and/or 
cellular proliferation (Fli1, Vav3, or EiF4E3), and the second 
one contains genes involved in calcium metabolism (calnexin 
and calumenin) that regulates T cell proliferation (Michalak 
et al., 2002; Medyouf et al., 2007). In addition to mRNAs 
whose levels were dependent on NKX3.1 expression, we found 
that miR-17-92 was directly regulated by NKX3.1. miR-19, 
a member of the miR-17-92 cluster, has been recently shown 
to promote leukemogenesis in a mouse Notch1-induced 
T-ALL (Mavrakis et al., 2010), and activation of miR-17-92 
by NKX2-5 suppresses apoptosis via reduction of E2F1 (Nagel 
et al., 2009). Our results indicated that NKX3.1 might be a 
possible link between TAL1 and the miR-17-92 transcriptional 
regulation in human T-ALL, but further studies are needed to 
precisely define the role of NKX3.1 on mature miRNA ex-
pression (particularly miR-19, derived from miR-17-92).
Patient-derived T-ALL cell lines may not totally reflect 
the original patient samples. To further explore the roles of 2152 NKX3.1 drives human T-ALL | Kusy et al.
Supersignal West Pico chemiluminescent substrate (Thermo Fisher Scientific). 
Hybridization signals were quantified by using the GS-800 calibrated densi-
tometer with Quantity One 1D analysis software (Bio-Rad Laboratories).
ChIP. Immunoprecipitation conditions were determined to ensure that the 
amount of antibody and percentage of cross-linking agent did not limit the 
ChIP yields. Cells (40 × 106) from the indicated cell lines were cross-linked 
for 10 min at 37°C with 1% formaldehyde in RPMI medium containing 
10% FCS, washed twice with ice-cold PBS, and lysed in 2 ml of ChIP lysis 
buffer for 10 min (50 mM Tris, pH 8.0, 10 mM EDTA, and 1% SDS). 
Chromatin fragments between 250 and 3,000 bp were obtained by sonica-
tion with a Sonifier 450 (Branson).
5 µg of antibodies against HP1- (Euromedex), H3K9me3 (Millipore), 
H3K14ac (Millipore), H3K4me3 (Millipore), and H3K27me3 (Millipore) 
was used to precipitate 1 µg of fragmented chromatin. Immunoprecipitations 
were performed in buffer containing 0.1% SDS, 1% Triton X-100, 2 mM 
EDTA, 20 mM Tris-HCl, pH 8.0, 150 mM NaCl, and a protease inhibitor 
cocktail (Roche) at 4°C overnight. A negative control without antibody or 
with control Ig was run simultaneously with the samples. Immunocom-
plexes were collected by adsorption to protein G agarose/Salmon Sperm 
DNA beads (Millipore). Washing and elution of immunocomplexes were 
performed, cross-linking was reversed for 5 h at 65°C, and samples were 
then treated with proteinase K (Invitrogen). Immunoprecipitated DNA was 
extracted with phenol-chloroform-isoamyl alcohol. The Bmi, Pax6, NKX3.1, 
RALDH2, and miR-17-92 promoters were assessed for the presence of his-
tone modifications using quantitative PCR. Amplification was performed 
using power SYBR green PCR Master mix (Applied Biosystems) supple-
mented with 0.5 µM of specific primer pairs and 100 ng DNA in a final vol-
ume of 20 µl. Amplification conditions included an initial denaturation at 
95°C for 10 min, followed by 35 cycles at 95°C for 15 s and 60°C for 60 s. 
Data were normalized to input signal and reported to IgG values ± SD.
4 µg -LMO1 (Abcam), 2 µg -LMO2, 2 µg -Ldb1, 5 µg -TAL1, 
5 µg –GATA-3, and 5 µg -NKX3.1 antibodies (Santa Cruz Biotechnology, 
Inc.) were used to precipitate 30 µg of fragmented chromatin. Immunopre-
cipitations were performed as described in the previous paragraphs, and 
PCR  amplifications  of  eluted  DNA  from  immunocomplexes  were  per-
formed in 20 µl of reaction mixture using the specific primers for the 
NKX3.1, RALDH2, and miR-17-92 promoters. Amplification conditions 
included an initial denaturation at 95°C for 5 min, followed by 35 cycles at 
94°C for 30 s, 55°C for 30 s, and 72°C for 30 s. The amplified DNA was 
separated on 2% agarose gels and visualized with ethidium bromide.
The sequences of the primers used were as follows: NKX3.1 promoter 
forward,  5-AACGCCTTCCATCCGTCTGG-3;  NKX3.1  promoter  re-
verse, 5-TGGTGCAAACTCAGATCTGC-3; NKX3.1 exon 2 forward, 
5-CCTCCCTGGTCTCCGTGTA-3; NKX3.1 exon 2 reverse, 5-TGT-
CACCTGAGCTGGCATTAC-3; 4-kb miR-17-92 regulatory sequence 
forward,  5-CCAGATAGCAAAGATATAACAG-3;  4-kb  miR-17-92 
regulatory sequence reverse, 5-CTTATATGAATCACGACTGAC-3; 
RALDH2 intron 2 forward, 5-AGAGTGTTCCCTGTCTATAATC-
CAGCC-3; RALDH2 intron 2 reverse, 5-TGTTAGAGAGGAAGAG-
GCACAACTGA-3; RALDH2 exon 6 forward, 5-AACTTCCCCCT-
GCTGATGTTTGCC-3; and RALDH2 exon 6 reverse, 5-CTTGAT-
GAGGGCTCCCATGTAGAGTGC-3.
For quantitative PCR, the primers used were as follows: NKX3.1 pro-
moter forward, 5-ATCATCTCTGTTCCACTTTCG-3; NKX3.1 pro-
moter reverse, 5-TAACCTGTTAACTTTCCTTCC-3; Pax6 promoter 
forward,  5-GTCCGGTGCCTTGAACCAT-3;  Pax6  promoter  re-
verse, 5-GCGCAACTACCGCCTCTAAA-3; Bmi promoter forward, 
5-CCAGTCTAGTGCATGCCTTCTTAA-3;  Bmi  promoter  reverse,   
5-CAAGCCAGCGACGCAGT-3; miR-17-92 promoter forward, 5-CCA-
GATAGCAAAGATATAACAG-3; and miR-17-92 promoter reverse, 
5-GTAACCTTGTTTGGGAAGACAC-3.
Real-time quantitative RT-PCR. Total RNA was isolated from 5 × 105 
cells using 1 ml TRIZOL reagent (Invitrogen) or the mirVana miRNA 
isolation kit (Applied Biosystems). RNA was reverse transcribed using 
encoding an shTAL1 or a control shCTL directed against the human hepa-
titis B virus have been described previously (Lazrak et al., 2004; Brunet de la 
Grange et al., 2006), and we also used another shTAL1 (5-GCAACATT-
GTTCACCTTTG-3) to avoid off-target effects. The human TAL1 coding 
sequence cloned under the EF1- promoter (TRIP/U3–EF1-–TAL1) 
has been described previously (Ravet et al., 2004). The human NKX3.1 
coding sequence was cloned into the pTRIPU3-Mnd-IRES-EGFP after 
PCR  amplification  using  primers  (forward)  5-GCGGGTGCATTCAG-
GCCAAGG-3  and  (reverse)  5-GGTGTGCACACCTCTTGCTCC-3 
and sequenced. Concentrated VSV/G pseudotyped shRNA and cDNA len-
tiviral vectors were produced as described previously (Ravet et al., 2004) and 
added to T-ALL cell lines cultured at a P24 concentration of 0.5 µg/ml twice 
at 24-h intervals. T-ALL samples were transduced with unconcentrated 
G/IL-7SUx envelope pseudotyped vectors (Verhoeyen et al., 2003) accord-
ing to Gerby et al. (2010). In brief, T-ALL samples were spinoculated for 2 h 
in the presence of plastic-bound human DL1, 5 µg/ml protamine sulfate, and 
G/IL-7SUx pseudotyped lentiviral vectors, and transduction was continued 
for a further 48 h. EGFP+ T-ALL primary cells were sorted (FACSAria; BD) 
and used in functional assays.
Cell cycle assay. Cells (106) were labeled with 10 µM BrdU for 45 min at 
days 1, 2, and 3 of culture. Cells were washed to remove BrdU and put in 
chase medium (RPMI 1640 and 1% FCS) or immediately fixed. After a chase 
period of 2 h, cells were fixed with 70% ethanol and stored overnight at 
20°C. After washing and centrifugation, cells were treated with 10 µg/ml 
RNase A for 20 min at 37°C. DNA was denatured with 2 N HCL/0.5% 
Triton X-100 for 30 min at 37°C to recover BrdU epitope and rinsed in 
PBS. Cells were incubated with FITC-conjugated mouse anti-BrdU anti-
body (1:10; BD) for 1 h at room temperature, washed in PBS, and then in-
cubated with 20 µg/ml propidium iodide before acquisition on the flow 
cytometer (Mow Flow Cytometer [Beckman Coulter] and FACSCalibur 
[BD]). Data were analyzed with FlowJo software (Tree Star, Inc.) for bivari-
ate analysis of DNA content versus BrdU.
Oligonucleotide pull-down. Cells were washed with PBS and incubated 
for 10 min at 4°C in buffer A (10 mM Hepes, pH 7.6, 3 mM MgCl2, 10 mM 
KCl, 5% glycerol, and 0.5% NP-40) containing proteinase inhibitor cocktail 
(Roche). After centrifugation, nuclear pellets were resuspended in buffer B 
(10 mM Hepes, pH 7.6, 3 mM MgCl2, 300 mM KCl, 5% glycerol, and 0.5% 
NP-40) and incubated for 30 min at 4°C. For oligonucleotide pull-down 
assays, nuclear extracts from Jurkat cells were incubated with 1 µg of the indi-
cated double-strand biotin-labeled oligonucleotide at 4°C overnight in buffer 
containing 10 mM Hepes, pH 7.6, 3 mM MgCl2, 150 mM KCl, 5% glycerol, 
and 0.5% NP-40. DNA–protein complexes were pelleted using streptavidin 
beads (GE Healthcare), and the beads were then washed three times with buf-
fer A, resuspended in Laemmli buffer, and subjected to immunoblotting analysis 
using antibodies against TAL1 or GATA-3 (Santa Cruz Biotechnology, Inc.).
Biotin-labeled oligonucleotides used for the oligonucleotide pull-down 
were as follows: E867, 5-biotin-TACATGTTAACAGTTGGTAATCT-
GCA-3; E800, 5-biotin-GCAGTTTTTGCATTTGTCCTGGCCTA-3; 
G748/E738,  5-biotin-GATGGTATGTCATGTGTCTGGGGAGG-3; 
G697, 5-biotin-GGTTATTGCGGATAAAGGAACCAC-3; and G577, 
5-biotin-TGAGGTCGTAGATATTGCAGATCT-3.
Immunoblotting analysis. Total proteins from 1–2 × 106 T-ALL cell lines 
were extracted with 1× Laemmli buffer. Proteins were separated by 12% SDS-
PAGE and transferred onto nitrocellulose membrane (Schleicher & Schuell). 
Membranes were incubated in Tris-buffered saline with 5% nonfat milk con-
taining antibodies against TAL1 (3BTL73 mouse monoclonal antibody pro-
vided by D. Mathieu [Centre National de la Recherche Scientifique Unité 
Mixte de Recherche 5535, Montpellier, France] or Santa Cruz Biotechnol-
ogy, Inc.), LMO1 (Abcam), Ldb1, GATA-3, E2F1, or NKX3.1 (Santa Cruz 
Biotechnology, Inc.). Normalization was performed using -actin (clone 
AC-15; Sigma-Aldrich) or ERK1/2 antibodies (Cell Signaling Technology). 
After staining with secondary antibodies, the proteins were detected with JEM VOL. 207, September 27, 2010 
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Microarray analyses were performed at the Institut de Génétique et de 
Biologie Moléculaire et Cellulaire French resource and by PartnerChip. 
HG-U133 Plus 2.0 array (Affymetrix) contains 54,600 human probe sets 
corresponding to 22,400 UniGene clusters. CEL files containing raw 
intensities were produced using GCOS (GeneChip operating software; 
Affymetrix). Data were normalized using GeneChip robust multi-array 
average, which generates intra- and interchip normalizations in a single step. 
Microarray data were submitted to ArrayExpress (deposited under accession 
no. E-MEXP-2197).
Promoter  in  silico  analysis.  NKX3.1  promoter  sequence  alignments 
were generated using ClustalW2 (http://www.ebi.ac.uk/Tools/clustalw2/
index.html). Mouse (promoter ID 55970) and human (promoter ID 41156) 
sequences were obtained from the Transcriptional Regulator Element Data-
base (http://rulai.cshl.edu/cgi-bin/TRED/tred.cgi?process=searchPromForm). 
The c13orf25 gene contains a polycistronic cluster of miRNAs (miR-17–92), 
and its promoter has been previously described (Ota et al., 2004; Woods 
et al., 2007).
Promoter reporter constructs, transient transfections, and luciferase 
assays. A 494-bp DNA fragment of the human NKX3.1 promoter spanning 
nt 977 to 482 relative to the start codon was amplified using the prim-
ers 5-ATGCCTCGAGATCATCTCTGTTCCACTTTCG-3 (forward) 
and 5-GCATTCTAGAGATGAGCACGCAGTCACTGC-3 (reverse). 
A 434-bp DNA fragment of the mouse NKX3.1 promoter spanning nt 
875 to 441 relative to the start codon was amplified using the primers 
5-ATGCCTCGAGACCTGGCTGTCCAAGAAATCC-3  (forward)  and 
5-GCATTCTAGAGAAGGTCCAAGTAGTATGAC-3 (reverse). The 
fragments were sequenced and cloned upstream from a TATA box sequence 
(5-TCTAGAGGGTATATAATGGATCTAAGTAAGCTT-3),  and  the 
resulting DNA fragments were cloned upstream from the firefly luciferase-
coding sequence in pGL2b (Promega). Mutations (base substitution) of the 
E-box E738 and the GATA motifs G748 and G697 in the human promoter 
were performed using the QuikChange II site-directed mutagenesis kit 
(Agilent Technologies). The binding site sequences 5-GATG-3 (G748), 
5-GATA-3  (G697),  and  5-CATGTG-3  (E738)  were,  respectively, 
mutated to 5-GCCC-3, 5-GCCC-3, and 5-CCTCGG-3 sequences. 
Jurkat cells or Jurkat shTAL1 (107) were electroporated in a volume of 150 µl 
of PBS-Hepes (10 mM, pH 7.4) by a single pulse of 200 V at 960 µF with a 
Gene Pulser apparatus (Bio-Rad Laboratories). 10 µg of reporter gene plas-
mid and 2 µg of pRL-TK plasmid (Promega) for normalization of transfec-
tion efficiency were used. Cells were stimulated with 1 µM ionomycin and 
50 ng/ml PMA (Sigma-Aldrich) and harvested 24 h after transfection. Lucif-
erase activities were determined using the dual-luciferase reporter assay sys-
tem as indicated by the manufacturer (Promega).
A 1612-bp DNA fragment of the human miR-17-92 promoter spanning 
nt 4840 to 3228 relative to the transcriptional start site was amplified using 
the primers 5-TACTGAGGTACCAAGTGCCCCCAGAAAGGCAA-3 
(forward)  and  5-TACTGACTCGAGCAAAGACCATAATCATTTA-
ACCTG-3 (reverse). The resulting DNA fragment was cloned into KpnI 
and XhoI sites of the pGL3-control vector (Promega) upstream from the 
firefly luciferase–coding sequence, sequenced, and cotransfected with 100 ng 
pcDNA3-NKX3.1 and Renilla luciferase vector (Promega) into HEK 293 
cells. Luciferase activities were determined using the dual-luciferase reporter 
assay system as indicated by the manufacturer (Promega).
Animals.  NOD.CB17-Prkdc(scid)  (abbreviated  NOD/scid;  NS)  and 
NOD.Cg-Prkdc(scid)Il2rg(tm1Wjll)/SzJ  (abbreviated  NOD/scid/IL-2R 
null; NSG; both from The Jackson Laboratory) were housed in pathogen-free 
animal facilities at the Commissariat à l’Energie Atomique et aux Energies Alter-
natives, Fontenay-aux-Roses, France. Mice were sublethally irradiated at 
3 Gy (IBL 637 CisBio International, France; dose rate 0.61 Gy/min) and 
anesthetized with isoflurane before i.v. injection of human leukemic trans-
duced (CD45+CD7+EGFP+; 5 × 104/mouse) cells. All experimental procedures 
were performed in compliance with French Ministry of Agriculture regulations 
(animal facility registration number A920322) for animal experimentation. 
random hexamers and the Superscript RT kit (Invitrogen) according to the 
manufacturer’s instructions. The cDNA reactions were diluted 1:10 in water 
and used as template in real-time PCR reactions using the power SYBR 
green PCR Master mix or the TaqMan Universal PCR MasterMix No 
AmpErase UNG (Applied Biosystems; supplemented with 0.5 µM specific 
probe for the specific primer pairs if necessary) in the 7300 fast real-time 
PCR system (Applied Biosystems). The cycle at which a particular sample 
reaches an arbitrary threshold fluorescent level (Ct) is indicative of the input 
quantity of the template. The raw data were obtained in terms of Ct values 
that refer to the PCR cycle number during exponential amplification at 
which the product crosses an arbitrary threshold. To adjust for variations in 
the amount of RNA, the Ct values for each gene were normalized against 
the Ct values for the housekeeping genes, GAPDH, 2m, or 36B4. The 
primer sequences used for real-time quantitative PCR were the following: 
GAPDH forward, 5-GGGAAACTGTGGCGTGAT-3; GAPDH reverse, 
5-GGAGGAGTGGGTGTCGCTGTT-3;  2m  forward,  5-CACAG-
CCCAAGATAGTTAAGT-3;  2m  reverse,  5-CCAGCCCTCCTAG-
AGC-3; NKX3.1 forward, 5-CCTCCCTGGTCTCCGTGTA-3; NKX3.1 
reverse, 5-TGTCACCTGAGCTGGCATTAC-3; TAL1 forward, 5-TCT-
GAAGCAAGGCGGTGGAC-3; TAL1 reverse, 5-GGAAGACCGTGCC-
GTCTTCA-3; Hes1 forward, 5-CAACACGACACCGGATAAACC-3; 
Hes1 reverse, 5-CCAGAATGTCCGCCTTCC-3; Deltex forward, 5-TTC-
TGACTTCAGGAGCGAAAG-3;  Deltex  reverse,  5-TGCCCACT-
CCCAACGA-3; E2F1 forward, 5-CCCAACTCCCTCTACCCTTGA-3; 
E2F1 reverse, 5-TCTGTCTCCCTCCCTCACTTTC-3; miR-17-92 
forward, 5-CAGTAAAGGTAAGGAGAGCTCAATCTC-3; miR-17-92 
reverse, 5-CATACAACCACTAAGCTAAAGAATAATCTGA-3; miR-
17-92 probe (200 nM final), FAM-TGGAAATAAGATCATCATGCC-
CACTTGAGAC-TAMRA; 36B4 forward 5- GATGCCCAGGGAAG-
ACAG-3;  36B4  reverse  5-TCTGCTCCCACAATGAAACAT-3;  and 
36B4 probe (50 nM final), FAM-GACCTGGA-TAMRA.
Microarray processing. Quality of RNA samples was assessed using RNA 
6000 Nano chips (Agilent Technologies), and quantity was assessed by mea-
suring the absorbance at 260 nm with ND-1000 (NanoDrop). cRNA was 
prepared by the PartnerChip Company according to the protocols of the 
manufacturer (Affymetrix). In brief, 2 µg of RNA samples was used to gen-
erate first-strand cDNA using a T7–oligo (dT) primer and the Superscript II 
RT (Invitrogen). Second-strand synthesis was achieved using a cocktail of 
enzymes from Escherichia coli (DNA ligase and DNA polymerase I), RNase 
H, and T4 DNA polymerase. Clean-up of double-stranded cDNA was per-
formed using the GeneChip Sample Cleanup Module (Affymetrix). In vitro 
transcription was performed in the presence of T7 RNA polymerase and a 
biotinylated nucleotide analogue/ribonucleotide mix for cRNA amplifica-
tion and biotin labeling (GeneChip IVT Labeling kit; Affymetrix). Resulting 
biotinylated cRNAs were cleaned up using the GeneChip Sample Cleanup 
Module and quantified by absorbance measurement at 260 nm (NanoDrop). 
Starting with 5 µg of total RNA yielded between 50 and 80 µg of purified 
cRNA. Then, 20 µg of cRNA from samples was incubated at 94°C for 
35 min in a fragmentation buffer to be reduced to a mean size of 35–200 nt 
and finally added to the hybridization buffer. Fragmented cRNAs were hy-
bridized on HG-U133 Plus 2.0 array (Affymetrix) for 16 h at 45°C together 
with internal hybridization controls (bioB, bioC, bioD, cre, and oligonucle-
otide B2). The washing and staining procedure was performed in the Fluid-
ics Station 450 (Affymetrix). Probe arrays were exposed to 10 washes in 
nonstringent wash buffer A (6× saline–Na phosphate–EDTA and 0.01% 
Tween 20) at 30°C, followed by 6 washes in stringent buffer B (100 mM 
2-[4-morpholino]ethanesulfonic acid, 0.1 M [Na+], and 0.01% Tween 20) at 
50°C. The biotinylated cRNAs were stained with 10 µg/ml of a streptavi-
din-phycoerythrin conjugate (SAPE) for 5 min at 35°C and washed again 
with nonstringent buffer A (10 washes at 30°C). An antibody amplification 
step was added using 0.1 mg/ml goat IgG and 3 µg/ml biotinylated anti-
streptavidin antibody followed by an additional SAPE stain (5 min at 35°C 
for each step). Finally, arrays were washed 15 times in nonstringent buffer A 
at 35°C before scanning in GeneChip Scanner 3000 (Affymetrix).2154 NKX3.1 drives human T-ALL | Kusy et al.
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shows that reduced TAL1 expression in Jurkat and HSB2 T cell lines is asso-
ciated with up- and down-regulation of a common set of genes. Fig. S3 
shows the sequence alignment of human and mouse NKX3.1 gene promoter 
regions and analysis of Nkx3.1 and Nkx2.9 mRNA expression levels per-
formed by global gene expression in transgenic mice. Fig. S4 shows the fixa-
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Notch pathway. Online supplemental material is available at http://www 
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